Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab
Supported by Phase 3 Study in Patients With Non-Squamous Non-Small Cell Lung Cancer
THOUSAND OAKS, Calif., Dec. 2, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215, a biosimilar candidate to Avastin® (bevacizumab). The companies believe this submission is the first bevacizumab biosimilar application submitted to the EMA.
"The submission of ABP 215 to the EMA is an important milestone as Amgen seeks to expand our oncology portfolio," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Amgen is comm...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news
More News: Allergy | Avastin | Cancer | Cancer & Oncology | European Medicines Agency (EMA) | Lung Cancer | Marketing | Non-Small Cell Lung Cancer | Pharmaceuticals | Study